{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T15:09:23Z","timestamp":1794236963493,"version":"4.9.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T00:00:00Z","timestamp":1496102400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1245\/s10434-017-5871-x","type":"journal-article","created":{"date-parts":[[2017,5,30]],"date-time":"2017-05-30T18:08:22Z","timestamp":1496167702000},"page":"2344-2352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Micro-RNA-130a-3p Regulates Gemcitabine\u00a0Resistance via PPARG in Cholangiocarcinoma"],"prefix":"10.1245","volume":"24","author":[{"given":"Kei","family":"Asukai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Konno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Iwagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadafumi","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihito","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideshi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,30]]},"reference":[{"key":"5871_CR1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1159\/000360502","volume":"32","author":"S Rizvi","year":"2014","unstructured":"Rizvi S, Gores GJ. Molecular pathogenesis of cholangiocarcinoma. Dig Dis 2014;32:564\u2013569.","journal-title":"Dig Dis"},{"key":"5871_CR2","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00595-015-1129-z","volume":"45","author":"T Uwagawa","year":"2015","unstructured":"Uwagawa T, Yanaga K. Effect of NF-\u03baB inhibition on chemoresistance in biliary\u2013pancreatic cancer. Surg Today 2015;45:1481\u20131488.","journal-title":"Surg Today"},{"key":"5871_CR3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/01.sla.0000150166.94732.88","volume":"241","author":"JY Jang","year":"2005","unstructured":"Jang JY, Kim SW, Park DJ, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg 2005;241:77\u201384.","journal-title":"Ann Surg"},{"issue":"3","key":"5871_CR4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00595-016-1362-0","volume":"47","author":"UF Wellner","year":"2017","unstructured":"Wellner UF, Shen Y, Keck T, Jin W, Xu Z. The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today 2017;47(3):271\u2013279.","journal-title":"Surg Today"},{"issue":"2","key":"5871_CR5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1007\/s00595-016-1354-0","volume":"47","author":"T Mizuno","year":"2017","unstructured":"Mizuno T, Ebata T, Yokoyama Y, et al. Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis. Surg Today 2017;47(2):182\u2013192.","journal-title":"Surg Today"},{"key":"5871_CR6","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273\u20131281.","journal-title":"N Engl J Med"},{"key":"5871_CR7","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/sj.bjc.6605958","volume":"103","author":"Y Tomimaru","year":"2010","unstructured":"Tomimaru Y, Eguchi H, Nagano H, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-\u03b1\/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 2010;103:1617\u20131626.","journal-title":"Br J Cancer"},{"key":"5871_CR8","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.bbrc.2011.09.124","volume":"414","author":"A Tomokuni","year":"2011","unstructured":"Tomokuni A, Eguchi H, Tomimaru Y, et al. miR-146a suppresses the sensitivity to interferon-\u03b1 in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2011;414:675\u2013680.","journal-title":"Biochem Biophys Res Commun."},{"key":"5871_CR9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrgastro.2010.188","volume":"8","author":"Z Wang","year":"2011","unstructured":"Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 2011;8:27\u201333.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"5871_CR10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-3-46","volume":"3","author":"XJ Zhang","year":"2010","unstructured":"Zhang XJ, Ye H, Zeng CW, He B, Zhang H, Chen YQ. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol 2010;3:46.","journal-title":"J Hematol Oncol"},{"key":"5871_CR11","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1097\/MPA.0b013e3181ba82e1","volume":"38","author":"JK Park","year":"2009","unstructured":"Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 2009;38:e190\u2013199.","journal-title":"Pancreas"},{"key":"5871_CR12","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1158\/0008-5472.CAN-09-4598","volume":"70","author":"S Ali","year":"2010","unstructured":"Ali S, Ahmad A, Banerjee S, et al. Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010;70:3606\u20133617.","journal-title":"Cancer Res"},{"key":"5871_CR13","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1158\/0008-5472.CAN-09-4467","volume":"70","author":"E Giovannetti","year":"2010","unstructured":"Giovannetti E, Funel N, Peters GJ, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010;70:4528\u20134538.","journal-title":"Cancer Res"},{"key":"5871_CR14","doi-asserted-by":"crossref","first-page":"e6816","DOI":"10.1371\/journal.pone.0006816","volume":"4","author":"Q Ji","year":"2009","unstructured":"Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4:e6816.","journal-title":"PLoS One."},{"key":"5871_CR15","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/bjc.2013.320","volume":"109","author":"Y Iwagami","year":"2013","unstructured":"Iwagami Y, Eguchi H, Nagano H, et al. miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Br J Cancer 2013;109:502\u2013511.","journal-title":"Br J Cancer"},{"key":"5871_CR16","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/bjc.2014.454","volume":"111","author":"S Hasegawa","year":"2014","unstructured":"Hasegawa S, Eguchi H, Nagano H, et al. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br J Cancer 2014;111:1572\u20131580.","journal-title":"Br J Cancer"},{"key":"5871_CR17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10552-006-0109-4","volume":"18","author":"MT Goodman","year":"2007","unstructured":"Goodman MT, Yamamoto J. Descriptive study of gallbladder, extrahepatic bile duct, and ampullary cancers in the United States, 1997-2002. Cancer Causes Control 2007;18:415\u2013422.","journal-title":"Cancer Causes Control"},{"key":"5871_CR18","first-page":"5558","volume":"60","author":"W Motomura","year":"2000","unstructured":"Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res 2000;60:5558\u20135564.","journal-title":"Pancreatic carcinoma cells. Cancer Res"},{"key":"5871_CR19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3892\/or.2015.4099","volume":"34","author":"H Jiang","year":"2015","unstructured":"Jiang H, Yu WW, Wang LL, Peng Y. miR-130a acts as a potential diagnostic biomarker and promotes gastric cancer migration, invasion and proliferation by targeting RUNX3. Oncol Rep 2015;34:1153\u20131161.","journal-title":"Oncol Rep"},{"key":"5871_CR20","doi-asserted-by":"crossref","first-page":"33269","DOI":"10.18632\/oncotarget.5037","volume":"6","author":"SH Lee","year":"2015","unstructured":"Lee SH, Jung YD, Choi YS, Lee YM. Targeting of RUNX3 by miR-130a and miR-495 cooperatively increases cell proliferation and tumor angiogenesis in gastric cancer cells. Oncotarget 2015;6:33269\u201333278.","journal-title":"Oncotarget"},{"key":"5871_CR21","doi-asserted-by":"crossref","first-page":"13387","DOI":"10.18632\/oncotarget.3874","volume":"6","author":"I St\u00fcckrath","year":"2015","unstructured":"St\u00fcckrath I, Rack B, Janni W, J\u00e4ger B, Pantel K, Schwarzenbach H. Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget 2015;6:13387\u201313401.","journal-title":"Oncotarget"},{"key":"5871_CR22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.bbrc.2012.07.127","volume":"425","author":"N Xu","year":"2012","unstructured":"Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q, et al. Upregulated miR-130a increases drug resistance by regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell. Biochem Biophys Res Commun 2012;425:468\u2013472.","journal-title":"Biochem Biophys Res Commun"},{"key":"5871_CR23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13046-016-0296-0","volume":"35","author":"Y Liu","year":"2016","unstructured":"Liu Y, Li Y, Wang R, et al. MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells. J Exp Clin Cancer Res 2016;35:19.","journal-title":"J Exp Clin Cancer Res"},{"key":"5871_CR24","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ccr.2014.04.021","volume":"25","author":"AD Rhim","year":"2014","unstructured":"Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014;25:735\u2013747.","journal-title":"Cancer Cell"},{"key":"5871_CR25","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","volume":"25","author":"BC \u00d6zdemir","year":"2014","unstructured":"\u00d6zdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014;25:719\u2013734.","journal-title":"Cancer Cell"},{"key":"5871_CR26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/35077241","volume":"411","author":"LA Liotta","year":"2001","unstructured":"Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001; 411:375-379.","journal-title":"Nature."},{"key":"5871_CR27","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1158\/0008-5472.CAN-07-5714","volume":"68","author":"RF Hwang","year":"2008","unstructured":"Hwang RF, Moore T, Arumugam T, et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008;68:918\u2013926.","journal-title":"Cancer Res"},{"key":"5871_CR28","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1261\/rna.642907","volume":"13","author":"Y Xi","year":"2007","unstructured":"Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007;13:1668\u20131674.","journal-title":"RNA"},{"key":"5871_CR29","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/bjc.2012.294","volume":"107","author":"JS Hall","year":"2012","unstructured":"Hall JS, Taylor J, Valentine HR, et al. Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. Br J Cancer 2012;107:684\u2013694.","journal-title":"Br J Cancer"},{"key":"5871_CR30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","volume":"19","author":"M Ahmadian","year":"2013","unstructured":"Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPAR\u03b3 signaling and metabolism: the good, the bad and the future. Nat Med 2013;19:557\u2013566.","journal-title":"Nat Med"},{"key":"5871_CR31","first-page":"5558","volume":"60","author":"W Motomura","year":"2000","unstructured":"Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res 2000;60:5558\u20135564.","journal-title":"Pancreatic carcinoma cells. Cancer Res"},{"key":"5871_CR32","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.3892\/ol.2014.2553","volume":"8","author":"I Ninomiya","year":"2014","unstructured":"Ninomiya I, Yamazaki K, Oyama K, et al. Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells. Oncol Lett 2014;8:2709\u20132714.","journal-title":"Oncol Lett"},{"key":"5871_CR33","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1038\/sj.onc.1209299","volume":"25","author":"Y Kato","year":"2006","unstructured":"Kato Y, Ying H, Zhao L, Furuya F, Araki O, Willingham MC, et al. PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 2006;25:2736\u20132747.","journal-title":"Oncogene"},{"key":"5871_CR34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1053\/gast.2003.50067","volume":"124","author":"E Osawa","year":"2003","unstructured":"Osawa E, Nakajima A, Wada K, et al. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003;124:361\u2013367.","journal-title":"Gastroenterology"},{"key":"5871_CR35","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/ncomms2270","volume":"3","author":"Y Hou","year":"2012","unstructured":"Hou Y, Moreau F, Chadee K. PPAR\u03b3 is an E3 ligase that induces the degradation of NF\u03baB\/p65. Nat Commun 2012;3:1300.","journal-title":"Nat Commun"},{"key":"5871_CR36","doi-asserted-by":"crossref","first-page":"8806","DOI":"10.1073\/pnas.95.15.8806","volume":"95","author":"E Elstner","year":"1998","unstructured":"Elstner E, M\u00fcller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 1998; 95:8806\u20138811.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5871_CR37","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.23550","volume":"51","author":"J Yu","year":"2010","unstructured":"Yu J, Shen B, Chu ES, et al. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology 2010; 51:2008\u20132019.","journal-title":"Hepatology"},{"key":"5871_CR38","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/cncr.27865","volume":"119","author":"KF Cheung","year":"2013","unstructured":"Cheung KF, Zhao J, Hao Y, et al. CITED2 is a novel direct effector of peroxisome proliferator-activated receptor \u03b3 in suppressing hepatocellular carcinoma cell growth. Cancer 2013; 119:1217\u20131226.","journal-title":"Cancer"},{"key":"5871_CR39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.bbrc.2015.08.012","volume":"465","author":"L Lu","year":"2015","unstructured":"Lu L, Wang J, Lu H, et al. MicroRNA-130a and -130b enhance activation of hepatic stellate cells by suppressing PPAR\u03b3 expression: a rat fibrosis model study. Biochem Biophys Res Commun 2015; 465:387\u2013393.","journal-title":"Biochem Biophys Res Commun"},{"key":"5871_CR40","doi-asserted-by":"crossref","first-page":"8523","DOI":"10.1038\/ncomms9523","volume":"6","author":"S Su","year":"2015","unstructured":"Su S, Zhao Q, He C, et al. miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program. Nat Commun 2015; 6:8523.","journal-title":"Nat Commun"},{"key":"5871_CR41","first-page":"679","volume":"40","author":"H Koga","year":"2012","unstructured":"Koga H, Selvendiran K, Sivakumar R, Yoshida T, Torimura T, Ueno T, et al. PPAR\u03b3 potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. Int J Oncol 2012; 40:679\u2013685.","journal-title":"Int J Oncol"},{"key":"5871_CR42","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004; 3:673\u2013683.","journal-title":"Nat Rev Drug Discov"},{"key":"5871_CR43","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo N. Can you teach old drugs new tricks? Nature 2016; 534:314\u2013316.","journal-title":"Nature"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-017-5871-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-017-5871-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-017-5871-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T23:47:52Z","timestamp":1602200872000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-017-5871-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,30]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["5871"],"URL":"https:\/\/doi.org\/10.1245\/s10434-017-5871-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,30]]}}}